Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 2 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM073597
Első szerző:
Gadó Klára
Cím:
Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients / Klára Gadó, György Nagy, Ágnes Hasitz, Béla E. Tóth, Éva Rimanóczi, Gyula Domján
Dátum:
2001
ISSN:
1021-7401
Megjegyzések:
The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.
Tárgyszavak:
Orvostudományok
Gyógyszerészeti tudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:
Neuroimmunomodulation 9 : 2 (2001), p. 95-102. -
További szerzők:
Nagy György
Hasitz Ágnes
Tóth E. Béla (1960-) (orvos)
Rimanóczi Éva
Domján Gyula
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM073598
Első szerző:
Gadó Klára
Cím:
Elevated levels of serum prolactin in patients with advanced multiple myeloma / Klára Gadó, Éva Rimanóczi, Ágnes Hasitz, Gábor Gigler, Béla E. Tóth, György M. Nagy, Katalin Pálóczi, Gyula Domján
Dátum:
2001
ISSN:
1021-7401
Megjegyzések:
The role of prolactin in immunoregulation and normal hemopoiesis is well known. However, prolactin also seems to be involved in the pathomechanism of malignancies and autoimmune diseases. Elevated serum prolactin levels were reported in patients with malignant lymphoma, colon and breast carcinoma, systemic lupus erythematosus and rheumatoid arthritis. Recently we demonstrated prolactin immunostaining in bone marrow cells of patients with multiple myeloma. Design and Methods: Serum prolactin levels of 56 patients with multiple myeloma, as well as serum ?2-microglobulin, and interleukin-6 concentrations were determined in this study. Results: Patients with advanced disease showed a significant increase in serum prolactin concentration, while patients with a clinical stage of I and II, and also control patients had normal values. The concentration of serum ?2-microglobulin and interleukin-6 changed in parallel with that of serum prolactin in patients with multiple myeloma. Determining serum prolactin levels several times during the disease process in a given patient clearly showed that the prolactin concentration was increasing during the disease progression. Interpretation and Conclusions: Our results indicate a role of prolactin in disease progression in multiple myeloma.
Tárgyszavak:
Orvostudományok
Gyógyszerészeti tudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:
Neuroimmunomodulation 9 : 4 (2001), p. 231-236. -
További szerzők:
Rimanóczi Éva
Hasitz Ágnes
Gigler Gábor
Tóth E. Béla (1960-) (orvos)
Nagy György M.
Pálóczy Katalin
Domján Gyula
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.